Corcept Therapeutics (CORT) PT Raised to $150 from $76 at Truist on 'Positive Ph3 ROSELLA Data'
Tweet Send to a Friend
(Updated - April 1, 2025 8:13 AM EDT)
Truist Securities analyst Joon Lee raised the price target on Corcept ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Truist Securities analyst Joon Lee raised the price target on Corcept ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
